Castration-resistant prostate cancer (CRPC), especially metastatic castration-resistant
prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of …

Develo** novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …

Personalized medicine tailors therapies, disease prevention, and health maintenance to the
individual, with pharmacogenomics serving as a key tool to improve outcomes and prevent …

Inflammation is a hallmark of cancer. In patients with cancer, peripheral blood myeloid
expansion, indicated by a high neutrophil-to-lymphocyte ratio, associates with shorter …

Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying
genomic instability through radiotherapy and chemotherapy has been a powerful but …

Background Metastatic castration-resistant prostate cancer is enriched in DNA damage
response (DDR) gene aberrations. The TOPARP-B trial aims to prospectively validate the …

Genomic instability is a hallmark of cancer, and often is the result of altered DNA repair
capacities in tumour cells. DNA damage repair defects are common in different cancer types; …

Genomic instability is a key hallmark of cancer that arises owing to defects in the DNA
damage response (DDR) and/or increased replication stress. These alterations promote the …

Purpose: Genomic alterations in DNA damage repair (DDR) genes other than BRCA may
confer synthetic lethality with PARP inhibition in metastatic castration-resistant prostate …

Background Homologous recombination repair deficiency (HRD) is a frequent feature of
high-grade serous ovarian, fallopian tube and peritoneal carcinoma (HGSC) and is …